3,748,800 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY bought a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 3,748,800 shares of the medical instruments supplier’s stock, valued at approximately $39,775,000. DENTSPLY SIRONA makes up 1.1% of Paradigm Capital Management Inc. NY’s holdings, making the stock its 21st largest position.

A number of other institutional investors have also recently bought and sold shares of the stock. Daiwa Securities Group Inc. increased its position in shares of DENTSPLY SIRONA by 2.9% during the fourth quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock worth $306,000 after acquiring an additional 767 shares in the last quarter. Blue Trust Inc. lifted its position in DENTSPLY SIRONA by 10.8% in the 1st quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 1,226 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in DENTSPLY SIRONA by 3.3% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 40,944 shares of the medical instruments supplier’s stock worth $475,000 after purchasing an additional 1,300 shares during the period. Empowered Funds LLC boosted its stake in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its holdings in DENTSPLY SIRONA by 13.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier’s stock worth $149,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors own 95.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on XRAY shares. Barclays boosted their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Mizuho cut their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Piper Sandler raised their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Finally, Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a report on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.54.

Insider Activity

In other news, Director Brian P. Mckeon bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. The trade was a 19.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is owned by insiders.

DENTSPLY SIRONA Stock Performance

XRAY opened at $10.89 on Tuesday. The business’s 50-day simple moving average is $12.04 and its 200 day simple moving average is $11.79. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63. The firm has a market capitalization of $2.17 billion, a PE ratio of -3.96, a PEG ratio of 1.38 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The business’s revenue was down 4.1% compared to the same quarter last year. During the same period last year, the company earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.41 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.